Amedisys, Inc. (NASDAQ:AMED) Shares Acquired by Bank of New York Mellon Corp

Bank of New York Mellon Corp increased its stake in shares of Amedisys, Inc. (NASDAQ:AMED - Free Report) by 22.6% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 298,870 shares of the health services provider's stock after acquiring an additional 55,073 shares during the period. Bank of New York Mellon Corp owned about 0.91% of Amedisys worth $27,134,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors also recently bought and sold shares of AMED. Blue Trust Inc. boosted its position in Amedisys by 55.1% in the 4th quarter. Blue Trust Inc. now owns 349 shares of the health services provider's stock worth $34,000 after purchasing an additional 124 shares in the last quarter. HBW Advisory Services LLC purchased a new stake in Amedisys during the fourth quarter worth $38,000. Versant Capital Management Inc grew its position in Amedisys by 68.5% during the fourth quarter. Versant Capital Management Inc now owns 450 shares of the health services provider's stock valued at $41,000 after buying an additional 183 shares during the period. KBC Group NV purchased a new position in Amedisys in the third quarter valued at $63,000. Finally, Venturi Wealth Management LLC boosted its stake in shares of Amedisys by 397.4% during the 4th quarter. Venturi Wealth Management LLC now owns 975 shares of the health services provider's stock worth $89,000 after acquiring an additional 779 shares in the last quarter. 94.36% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Separately, Stephens reiterated an "equal weight" rating and set a $101.00 price target on shares of Amedisys in a research report on Tuesday, March 4th. Five investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Hold" and an average price target of $100.75.

Remove Ads

Amedisys Price Performance

Amedisys stock traded up $0.07 during midday trading on Wednesday, reaching $92.16. The company had a trading volume of 307,878 shares, compared to its average volume of 378,579. The company has a debt-to-equity ratio of 0.05, a current ratio of 1.19 and a quick ratio of 1.19. Amedisys, Inc. has a 12-month low of $82.15 and a 12-month high of $98.95. The company has a market capitalization of $3.02 billion, a P/E ratio of 36.58, a P/E/G ratio of 1.78 and a beta of 0.76. The firm's fifty day simple moving average is $92.06 and its 200-day simple moving average is $92.86.

Amedisys (NASDAQ:AMED - Get Free Report) last released its earnings results on Wednesday, February 26th. The health services provider reported $0.96 earnings per share for the quarter, missing the consensus estimate of $1.05 by ($0.09). Amedisys had a net margin of 3.57% and a return on equity of 12.20%. The firm had revenue of $598.05 million during the quarter, compared to analysts' expectations of $602.38 million. As a group, equities analysts anticipate that Amedisys, Inc. will post 4.4 EPS for the current year.

About Amedisys

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.